Compare Asana Inc. (ASAN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs Sana Biotechnology Inc — how do they compare? Asana Inc. trades at $9.16 (market cap $2.13B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Asana Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.
| ASAN | SANA | |
|---|---|---|
Market Cap | $2.13B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $5.92 |
52-Week Low | $5.46 | $2.68 |
Enterprise Value | $1.96B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $9.065, down 1.79% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is strong, reaching $723.88M in 2025, yet the company remains unprofitable with a net income margin of -20.21%. Recent earnings beats and AI product developments, including the StackAI acquisition, highlight operational momentum amid competitive pressures.
The outlook is mixed: analyst consensus leans neutral with a $10.33 price target, suggesting modest upside, but persistent losses and high valuation ratios pose risks. Key catalysts include continued AI integration and FedRAMP authorization, while decelerating revenue growth and competition from tech giants remain headwinds for shareholder value.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
